scholarly journals Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy

2022 ◽  
Vol 36 ◽  
pp. 19-22
Author(s):  
Sebastiaan Remmers ◽  
Daan Nieboer ◽  
L. Lucia Rijstenberg ◽  
Tim Hansum ◽  
Geert J.L.H. van Leenders ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Intraductal Carcinoma ◽  
Risk Calculator ◽  
Negative Biopsy

scholarly journals Next-generation prostate cancer risk calculator for primary care physicians

2017 ◽  
Vol 12 (2) ◽  
pp. E64-70 ◽  
Author(s):  
Robert K. Nam ◽  
Raj Satkunasivam ◽  
Joseph L. Chin ◽  
Jonathan Izawa ◽  
John Trachtenberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Life Expectancy ◽  
Prostate Biopsy ◽  
Primary Care Physicians ◽  
Prostate Cancer Risk ◽  
Concordance Index ◽  
Risk Calculator ◽  
Next Generation ◽  
Term Survival

Introduction: Current prostate cancer risk calculators are limited in impact because only a probability of having prostate cancer is provided. We developed the next generation of prostate cancer risk calculator that incorporates life expectancy in order to better evaluate prostate cancer risk in context to a patient’s age and comorbidity.Methods: We combined two cohorts to develop the new risk calculator. The first was 5638 subjects who all underwent a prostate biopsy for prostate cancer detection. The second was 979 men diagnosed with prostate cancer with long-term survival data. Two regression models were used to create multivariable nomograms and an online prostate cancer risk calculator was developed.Results: Of the 5638 patients who underwent a prostate biopsy, 629 (11%) were diagnosed with aggressive prostate cancer (Gleason Score 7[4+3] or more). Of the 979 patients who underwent treatment for prostate cancer, the 10-year overall survival (OS) was 49.6% (95% confidence interval [CI] 46.6‒52.9). The first multivariable nomogram for cancer risk had a concordance index of 0.74 (95% CI 0.72, 0.76), and the second nomogram to predict survival had a concordance index of 0.71 (95% CI 0.69‒0.72). The nextgeneration prostate cancer risk calculator was developed online and is available at: http://riskcalc.org/ProstateCA_Screen_Tool.Conclusions: We have developed the next-generation prostate cancer risk calculator that incorporates a patient’s life expectancy based on age and comorbidity. This approach will better evaluate prostate cancer risk. Future studies examining other populations will be needed for validation.

PROSTATE BIOPSY OUTCOME PREDICTION – COMPARISON OF A NOVEL LOGISTIC REGRESSION-BASED MODEL, THE PROSTATE CANCER RISK CALCULATOR AND PSA ALONE

2008 ◽  
Vol 179 (4S) ◽  
pp. 640-641
Author(s):  
David J Hernandez ◽  
Misop Han ◽  
Elizabeth B Humphreys ◽  
Leslie A Mangold ◽  
Michael K Brawer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Logistic Regression ◽  
Cancer Risk ◽  
Prostate Biopsy ◽  
Outcome Prediction ◽  
Prostate Cancer Risk ◽  
Risk Calculator

scholarly journals An Irish prostate cancer risk calculator

2016 ◽  
Vol 36 ◽  
pp. S123
Author(s):  
R. Foley ◽  
K. Murphy ◽  
R. Maweni ◽  
T. Lynch ◽  
R. Power ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Risk Calculator

scholarly journals PROSTATE CANCER RISK CALCULATOR COMPARISON: IPCRC vs KPCRC vs PCPT-RC vs ERSPC-RC IN PREDICTING PROSTATE CANCER AT HASAN SADIKIN HOSPITAL

2017 ◽  
Vol 24 (2) ◽  
Author(s):  
Christiano Tansol ◽  
Ferry Safriadi
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Prostate Volume ◽  
Randomized Study ◽  
Transrectal Ultrasound ◽  
Digital Rectal Examination ◽  
Prostate Cancer Risk ◽  
Risk Calculator ◽  
Chi Square ◽  
Chi Square Analysis

Objective: To compare the validated calculators of Indonesian Prostate Cancer Risk Calculator  (IPCRC) vs Korean Prostate Cancer Risk Calculator (KPCRC) vs Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) vs European Randomized Study of Screening for Prostate Cancer Risk Calculator (ERSPC-RC) in predicting prostate cancer in our patients at Hasan Sadikin Hospital Bandung. Material & methods: This study is a prospective study conducted from August 2014 – December 2015 at Urology Clinic at Hasan Sadikin Hospital that included all patients with BPH or suspected PCa who have been undergoing prostate biopsy. Variables such as age, PSA level, prostate volume (transabdominal or transrectal ultrasound) and digital rectal examination (DRE) finding were recorded. Risk calculation was generated using each risk calculator. Data were analyzed using Chi-square analysis, Kolmogorov-Smirnov, and finally receiver operating characterisitic (ROC) curve. All statistical analyses were performed with SPSS version 20.  Results: There were 89 BPH and 43 PCa patients between August 2014 – December 2015. The mean age, PSA and prostate volume are 65.78 ± 8.33 years; 121.16 ± 375.76ng/ml; 55.86 ± 31.9ml respectively. Abnormal DRE was found in 27 PCas and 4 BPHs. Receiver operator curve analysis of IPCRC showed AUC 0.861 vs KPCRC (AUC=0.779) vs ERSPC-RC (AUC=0.745) vs PCPT-RC (AUC=0.794) vs PSA (AUC 0.794), sensitivity 81.4% and specificity 71.9% with cut-off point 19.67 for the IPCRC in predicting the prostate cancer in our center. Conclusion: IPCRC is better than KPCRC, PCPT-RC and ERSPC-RC in predicting prostate cancer in our center.

Sign in / Sign up

Export Citation Format

Share Document